Anbio Biotechnology (NASDAQ:NNNN) Sees Significant Growth in Short Interest

Posted by ABMN Staff on Jun 1st, 2026

Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 92,563 shares, a growth of 111.7% from the April 30th total of 43,717 shares. Based on an average daily volume of 22,120 shares, the days-to-cover ratio is currently 4.2 days. Currently, 0.1% of the company’s shares are sold short.

Anbio Biotechnology Price Performance

NASDAQ:NNNN opened at $34.41 on Monday. Anbio Biotechnology has a 1-year low of $7.67 and a 1-year high of $55.65. The company has a fifty day moving average of $27.42.

Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) last released its quarterly earnings results on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Check Out Our Latest Research Report on NNNN

About Anbio Biotechnology

(Get Free Report)

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.